Company Presentation

Amphilix has a First-I in-Class small molecule based radioligand for the treatment of Colorectal Cancer. We differentiate from competition in the following 3 aspects::
a) new target highly expressed in Colorectal cancer cells (and other tumors) and in tumor-associated growing blood vessels
b) small molecule-based ligand has a long residence time
c) proprietary 3D linker platform enabling excellent drug properties